|Drug Patent Number||Company||Drug Patent Title||Drug Patent Expiry||Activity Alert|
|These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.|
|US7351401||GE HEALTHCARE||Thioflavin derivatives for use in the antemortem diagnosis of Alzheimers disease and in vivo imaging and prevention of amyloid deposition|| |
(8 months ago)
|US8236282||GE HEALTHCARE||Benzothiazole derivative compounds, compositions and uses|| |
(7 months from now)
|US7270800||GE HEALTHCARE||Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition|| |
(1 year, 10 months from now)
|These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US8691185||GE HEALTHCARE||Benzothiazole derivative compounds, compositions and uses|| |
(8 months ago)
|US8916131||GE HEALTHCARE||Radiopharmaceutical composition|| |
(4 years from now)
Vizamyl is owned by Ge Healthcare.
Vizamyl contains Flutemetamol F-18.
Vizamyl has a total of 5 drug patents out of which 2 drug patents have expired.
Expired drug patents of Vizamyl are:
Vizamyl was authorised for market use on 25 October, 2013.
Vizamyl is available in injectable;intravenous dosage forms.
Vizamyl can be used as diagnostic radioimaging.
The generics of Vizamyl are possible to be released after 16 September, 2028.
Market Authorisation Date: 25 October, 2013
Treatment: Diagnostic radioimaging
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic